Different mechanisms are implicated in ERBB2 gene D Vernimmen

Different mechanisms are implicated in ERBB2 gene
overexpression in breast and in other cancers
D Vernimmen
1
, M Gueders
1
, S Pisvin
2
, P Delvenne
2
and R Winkler*
,1
1
Molecular Oncology Laboratory, Experimental Cancer Research Center, Lie
`ge University, B-4000 Lie `ge, Belgium;
2
Pathology Department, Experimental
Cancer Research Center, Lie
`ge University, B-4000 Lie `ge, Belgium
The ERBB2 gene is overexpressed in 30% of breast cancers and this has been correlated with poor prognosis. ERBB2 is upregulated
in other cancers such as prostate, pancreas, colon and ovary. In breast cancer cells, the mechanisms leading to ERBB2 gene
overexpression are increased transcription and gene amplification. In these cancers, AP-2 transcription factors are involved in ERBB2
overexpression, and AP-2 levels are correlated with p185
c-erbB-2
levels. In this work, we wanted to know if the same molecular
mechanisms are responsible for the ERBB2 upregulation in non-breast cancers. We compared ERBB2 gene copy number, p185
c-erbB-2
and mRNA levels with AP-2 levels in several ovary, prostate, colon and pancreas cancer cells. A moderate expression of erbB-2
mRNA and protein were observed in some cells without gene amplification. In contrast to breast cancer cells, AP-2 factors were
absent or low in some non-breast cells which did express ERBB2. It is thus likely that AP-2 is not a major player in the increased levels
of erbB-2 transcripts in non-breast cancer cells. The transcriptional activity of the ERBB2 promoter in colon and ovary cancer cells was
estimated using reporter vectors. The results showed that the promoter regions involved in ERBB2 gene overexpression in breast
cancer cells are different from those that lead to the gene upregulation in colon and ovary cancers. In conclusion, our results indicate
that different transcriptional and post-transcriptional mechanisms are responsible for the increased levels of erbB-2 transcript and
protein in breast and non-breast cancer cells.
British Journal of Cancer (2003) 89, 899 –906. doi:10.1038/sj.bjc.6601200 www.bjcancer.com
&2003 Cancer Research UK
Keywords: immunocytochemistry; ERBB2 promoter; AP-2 transcription factor; human
The ERBB2 gene is located on chromosome 17q21 and encodes a
185 kDa transmembrane receptor (p185
c-erbB-2
) belonging to the
EGFR family (Yarden and Sliwkowski, 2001). ERBB2 is over-
expressed in about 30% of breast and ovary cancers and this has
been correlated with poor prognosis for the patient (Ross and
Fletcher, 1999). Recently, the use of a p185
c-erbB-2
targeted
antibody, trastuzumab (Herceptin), has been used successfully to
inhibit the growth of breast cancer cells.
Most of the studies aimed at understanding the molecular basis
of ERBB2 overexpression have been performed in breast cancers.
In these cancers, the molecular mechanisms involved are
transcriptional upregulation and gene amplification (Hollywood
and Hurst, 1993; Pasleau et al, 1993). AP-2 and Ets family
transcription factors have been shown to contribute to ERBB2
overexpression in breast cancer cells. The AP-2 transcription
factors upregulate the ERBB2 expression by binding to two
sites located 213 bp (Bosher et al, 1996) and 500 bp
upstream the Cap site (Vernimmen et al, 2003). The Ets
transcription factor stimulates ERBB2 expression by preventing
the formation of a triplex structure on the core promoter (Scott
et al, 2000).
The ERBB2 gene is also overexpressed in other cancers such as
prostate, colon and pancreas cancers, and this alteration has also
been considered as a negative prognosis marker by some authors
(Klapper et al, 2000).
In this report, we address, for the first time, the molecular
mechanisms leading to ERBB2 gene overexpression in non-breast
cancer cells. We wanted to know if the mechanisms, which have
been shown to operate in breast cancers, are also at work in non-
breast cancers. For this purpose, we used cell lines derived from
ovary, prostate, colon, liver and pancreas cancers. First, we
compared the ERBB2 gene copy number, mRNA and protein
levels. The p185
c-erbB-2
levels were estimated by immunocytochem-
istry (ICC) and Western blotting. The ERBB2 gene copy numbers
and mRNA levels were measured by real-time PCR. In parallel, we
assessed the AP-2 levels and DNA binding activities in all these cell
lines. The results showed a moderate ERBB2 overexpression in a
significant proportion of non-breast cancer cells. Contrary to the
results obtained in breast cancer cell lines, there was no correlation
between the levels of the erbB-2 mRNA and the AP-2 transcription
factor. We then analysed the ERBB2 promoter activity in the
different cell lines by transfecting reporter vectors containing
progressive deletions of a 6 kb promoter (Grooteclaes et al, 1994).
The transcriptional activity increased with increasing sizes of the
ERBB2 promoter. Nevertheless, the regulatory fragments we
identified in breast cancer cells (Grooteclaes et al, 1994) function
differently in non-breast cancer cells. In conclusion, the accumula-
tion of erbB-2 mRNA and protein in breast and non-breast cancer
Received 19 February 2003; revised 19 June 2003; accepted 24 June
2003
*Correspondence: Dr R Winkler; E-mail: [email protected]
British Journal of Cancer (2003) 89, 899 – 906
&
2003 Cancer Research UK All rights reserved 0007 – 0920/03 $ 25.00
www.bjcancer.com
Molecular and Cellular Pathology

cells are the consequences of different transcriptional and/or post-
transcriptional events.
MATERIAL AND METHODS
Cell lines
The mammary (BT-474, ZR-75.1 and MDA-MB-231), hepatic
(HepG2), prostatic (LNCaP, DU 145 and PC-3), colon (WiDr,
HTm29, HCT 116, COLO 205 and COLO 320), ovary (OVCAR-3
and SK-OV-3) and pancreatic (PANC-1, Miapaca-2, HS766 T, CF-
PAC-1, SU.86.86, BxPC-3 and Capan-2) human epithelial cells were
purchased from American Type Culture Collection (Manassas, VA,
USA) and cultured in the recommended media supplemented with
10% fetal bovine serum, 2 mMglutamine and 100 mgml
1
penicillin/streptomycin. (Biowhittaker, Walkersville, MD, USA).
Immunocytochemistry
Cells (50 10
6
) were harvested by trypsinisation and centrifuga-
tion. After centrifugation, the cell pellets were fixed in 2%
paraformaldehyde (UCB, Louvain, Belgium), then embedded
in paraffin. Sections (5 mm thick) were deparaffinized and
rehydrated using xylene and graded alcohols. The sections were
heated at 1001C for 40 min in a citrate buffer, then incubated
for 20 min at room temperature. Endogenous peroxidase
activity was blocked with 5% H
2
O
2
for 5 min. After two washes,
for 5 min each, with 1% tween-phosphate-buffered saline
(PBS) solution, the sections were incubated with an antibody
diluent solution (Dako Diagnostics, Glostrup, Denmark) contain-
ing a c-erbB-2 monoclonal antibody (1 : 300) raised against
the internal domain of the p185
c-erbB-2
protein (NCL-CB11,
Novocastra, Newcastle, UK). Anti-mouse HRP-labelled polymer
(Dako) was applied for 30 min at room temperature and the slides
were washed for 2 5 min with 1% tween-PBS solution. The
sections were then incubated for 40 min with DAB
þ
substrate
(Dako), washed three to four times in water and counterstained
with haematoxylin. Cytoplasmic and membrane immunostaining
was evaluated using a 0 to 3 þscale (0, negative or equivocal
positivity; 1 þ, weak positivity; 2 þmoderate positivity; 3 þ
strong positivity).
Real-time PCR and real-time RT–PCR
Genomic DNA was extracted by the phenol –chloroform procedure
(Maniatis et al, 1982). Total cellular RNA was extracted with the
Tripure Isolation Reagent (Roche Diagnostic, Basel, Switzerland).
DNA and RNA quantification were performed with the Light-
Cycler– HER2/neu DNA and RNA Quantification Kits (Roche).
Electromobility shift assays (EMSA)
Nuclear extracts, HTF/AP-2 cis sequence and EMSA were
described elsewhere (Schreiber et al, 1989; Vernimmen et al,
2003). Briefly, 2– 4 mg of crude nuclear proteins were incubated
with 300 000 c.p.m. of [a-
32
P]dCTP end-labelled oligonucleotide.
The retarded complexes were analysed on a nondenaturing 5%
polyacrylamide gel and analysed using a PhosphorImager
(Molecular Dynamics Amersham Biosciences, Roosendal, The
Netherlands).
Western blotting
For p185
c-erbB-2
detection, cells were scraped off the culture
dishes, harvested in PBS, pelleted by centrifugation, resuspended
in a 1% SDS solution and boiled for 10 min. Whole cell
extracts (20 mg) were loaded per well, separated on a 12%
SDS– polyacrylamide gel and transferred to a PVDF membrane
(Millipore, Brussels, Belgium). A c-erbB-2 antibody (06-562
Euromedex, Mundolsheim, France) was used at a 1 : 2000 dilution.
For AP-2 detection, 10–25 mg of nuclear extracts were loaded
per well. An AP-2aantibody (sc-184 Santa Cruz Biotechnology,
Santa Cruz, CA, USA) was used at a 1 : 700 dilution. Secondary
antibodies (Dako Diagnostics, Glostrup, Denmark) were
detected with the ECL system (Amersham BioSciences). The
b-actin monoclonal antibody was from Sigma (monoclonal
(amoeba) mouse ascites fluid clone KJ43A Sigma-Aldrich Bernem,
Belgium).
Plasmids and transient transfection assays
The transfection efficiencies of all the cell lines were tested by
transfection of the pEGFP-IRESpuro control vector (Clontech, Palo
Alto, CA, USA). Cells were transfected using the FuGENE 6 reagent
(Roche). Cells (4 10
5
) were plated on 35 mm tissue culture dishes
with a FuGENE/DNA ratio of 3 : 1. The cells were incubated for 48 h
in complete medium. Cells transfected with the green fluorescent
protein (GFP) expression plasmid were visualised by fluorescent
microscopy. The luciferase (LUC) reporter vectors containing
different ERBB2 promoter fragments have been previously
described (Grooteclaes et al, 1994). The LUC enzymatic activities
were measured using the Luciferase Reporter Gene Assay kit
(Roche).
RESULTS
ErbB-2 gene copy number, mRNA and protein levels in
cancer cell lines
We measured the p185
c-erbB-2
protein levels by ICC and Western
blotting. For ICC, we used the well characterised breast cancer cell
lines BT-474 and ZR-75-1 as standards to determine the erbB2
expression in the non-breast cells (Figure 1A, C). After ICC,
p185
c-erbB-2
appeared as a brown membrane staining in positive
breast cancer cells. Likewise, p185
c-erbB-2
exhibited an intense
membranous staining in SK-OV-3 ovary carcinoma cells
(Figure 1B). P185
c-erbB-2
was detected in one out of two ovary,
four out of five colorectal, three out of three prostatic and only two
out of seven pancreatic cancer cells, but the staining was
heterogeneous and mainly cytoplasmic (Figure 1D and Table 1).
P185
c-erbB-2
was also detected in the cytoplasm of HepG2
hepatocarcinoma cells (Figure 1E). Figure 1F presents a pancreatic
cell line negative for p185
c-erbB-2
.
The p185
c-erbB-2
levels were also estimated by Western blotting
of whole-cell extracts (Table 1 and Figure 4). As cell density
has been reported to modulate p185
c-erbB-2
levels in breast cancer
cells (Kornilova et al, 1992), we compared the oncoprotein levels
in low (50% confluence)- and high (100% confluence)-density
cultures. The full-length, 185 kDa protein, was detected in most
analysed cells. A slight difference was observed between low-
and high-density cultures of breast, ovary and pancreatic cell
lines (Figure 4). The highest p185
c-erbB-2
levels were observed
in BT-474 breast and SK-OV-3 ovary cancer cells (Table 1). In
order to compare the protein content between the different
cancer types, we attributed the value of one to the p185
c-erbB-2
measured in MDA-MB-231 mammary cancer cells (Table 1).
BT-474 and SK-OV-3 cells contained the highest protein
levels associated with gene amplification and mRNA overexpres-
sion. Among the cells without gene amplification, HepG2
hepatocarcinoma and LNCaP prostate cancer cells were most
enriched in p185
c-erbB-2
. All the colon cancer cell lines contained
almost similar protein levels not significantly different from
that of MDA-MB-231 cells. The pancreatic cell lines SU.86.86,
BxPC-3, HS766 T and PANC-1 contained very low levels of
p185
c-erbB-2
, detectable only after long exposure time. Only
ERBB2 gene expression in human cancer cells
D Vernimmen et al
900
British Journal of Cancer (2003) 89(5), 899 – 906 &2003 Cancer Research UK
Molecular and Cellular Pathology

CF-PAC-1, Miapaca-2 and Capan-2 cells attained or slightly
exceeded the MDA-MB-231 p185
c-erbB-2
levels. Notice the wide
variation in p185
c-erbB-2
between the pancreatic cancer cells. In
general, Western blotting and ICC results were in reasonably good
agreement (Table 1).
The erbB-2 mRNA levels were measured by real-time RT–PCR.
The results are summarised in Table 1 and compared to the
Western blotting data. In most cells, real-time RT– PCR and
Western blotting data were in good agreement, except for the
COLO 320 cancer cells. Indeed, in these cells, the increase in
transcript levels was not accompanied by an increase in protein
levels (Table 1). Like the protein levels, erbB-2 mRNA levels were
quite high in HepG2 cells.
The ERBB2 gene copy numbers were estimated by real-time
PCR in all cancer cells (Table 1). The gene was not amplified
in any of the prostate, colon and pancreatic cancer cells.
SK-OV-3 presents a four-fold amplification of the ERBB2
gene.
Figure 1 Representative examples of p185
c-erbB-2
immunostaining in
cancer cell lines. (A) BT-474 (mammary cell line with ERBB2 amplification
and 3 þmembrane overexpression). (B) SK-OV-3 (ovary cell line with
ERBB2 amplification and 3 þmembrane overexpression). (C) ZR-75.1
(mammary cell line without ERBB2 amplification and 2 þmembrane
overexpression). (D) HTm29 (colon cell line without ERBB2 amplification
and 2 þcytoplasmic/1 þmembrane overexpression). (E) HepG2 (liver
cell line without ERBB2 amplification and 2 þcytoplasmic overexpression).
(F) SU.86.86 (pancreatic cell line without ERBB2 amplification and no
cytoplasmic/membrane expression)(magnification X400).
Table 1 ERBB2 gene amplification, mRNA and protein levels in cancer cell lines.
Origin Breast Ovary Prostate Colon Liver Pancreas
Cell line
MDA-
MB-231
BT –
474
OVCAR-3 SK-
OV-3
DU
145 PC-3 LNCaP HTm29 WiDr HCT116
COLO
205
COLO
320 HepG2 SU.86.86
B
PC-3 HS766T PANC-1
CF-
PAC-1 Miapaca-2 Capan-2
ICC M 0 3+ 0 3+ 0 0 0 1+ 0 0 0 0 0 0 0 0 0 0 0 0
C00001+1+2+2+1+01+
2+
0 0 0 0 1+ 0 1+
Wb Protein 1 15* 2 13* 1.5 1 7.5 2 1 1 3 1 11 0.10 0.05 0.15 0.25 2.10 1.60 2.30 RT – PCR RNA 1 70 1 60 0.2 0.3 2.2 0.5 1 2 2 6.5 6.5 0.04 0.06 0.04 0.05 1 1.1 1.7 PCR DNA 1 8 1 4 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The membrane (M) and cytoplasmic (C) staining (IHC) of p185
erbB2
is expressed as values comprised between 0 (no staining) and 3+ (intense staining). Western blotting (Wb) was performed using 20 mg of whole cell extracts.
Expression patterns were obtained by comparing the p185
erbB2
and b-actin levels in each cell line. ERBB2 mRNA levels were measured by real – time RT – PCR and compared to G6PD levels as the internal control for each cell line.
The values for mRNA and protein levels measured in all the cell lines were referred to the values in MDA-MB-231 cells considered as equal to 1. Gene copy number was estimated by real – time PCR. The values marked by an asterisk are underestimated due to the saturation of the film.
ERBB2 gene expression in human cancer cells
D Vernimmen et al
901
British Journal of Cancer (2003) 89(5), 899 – 906&2003 Cancer Research UK
Molecular and Cellular Pathology

AP-2 transcription factors are not involved in ERBB2
overexpression in non-breast cancer cells
AP-2 levels are high in most breast cancer cells overexpressing
ERBB2 (Bosher et al, 1996). To find out if these transcription
factors are also involved in the stimulation of ERBB2 expression
in non-breast cancer cells, we compared AP-2 and erbB-2 levels
in the cell lines used in this study. AP-2alevels were estimated
by Western blotting (Figure 2A) and AP-2 DNA binding activity
was analysed by gel retardation experiments (EMSA) (Figure 2B).
BT-474 and ZR-75.1 breast cancer cells were used as AP-2-positive
controls and HepG2 hepatocarcinoma cells and MDA-MB-231
breast cancer cells as AP-2-negative controls (Bosher et al, 1996).
AP-2 levels were very low in colon cancer cells (Figure 2A, lanes
8– 12). Interestingly, in COLO 205 cells, the AP-2 antibody
revealed three intense bands of lower molecular weight
(Figure 2A, lane 11). No DNA binding activity was detected
in these cells (Figure 2B, lane 11), suggesting that this might be
a false positive signal. Low levels of the 50 kDa AP-2 factor
were detected in prostate cancer cells (Figure 2A, lanes 5 –7). In
the two ovary cancer cell lines, AP-2awas easily detected
(Figure 2A, lanes 13, 14). However, the signal was much less
intense than in breast cancer cells overexpressing AP-2 (see
for instance Figure 2A, lanes 1 and 3). Finally, in the pancreatic
cells, the AP-2alevels were low to moderate. In these cells,
a higher molecular weight band was detected together with
the 50 kDa protein (Figure 2A, lanes 15–21). The Western blotting
and the EMSA results showed comparable patterns in all the
cell lines, indicating that when AP-2 was present, it binds
efficiently to DNA.
In conclusion, there was no correlation between AP-2 and erbB-
2 mRNA or protein levels in the non-breast cancer cell lines. The
most striking discrepancy was observed with HepG2 cells, widely
used as AP-2 negative controls, but these cells do express the erbB-
2 mRNA and protein. Our results thus suggest that the AP-2 is not
involved in ERBB2 overexpression in the non-breast cancer cell
lines we tested.
ERBB2 promoter activity in non-breast cancer cells
In order to better understand the mechanisms leading to ERBB2
overexpression in the non-breast cancer cells, we transfected
reporter vectors containing progressive deletions of a 6 kb
promoter fragment (Figure 3A). We have shown previously that
these promoter fragments are active in breast cancer cells
(Grooteclaes et al, 1994). The transfection efficiencies of all the
cell lines were estimated by transfection of an EGFP-expression
vector (data not shown). Only the cells having a transfection
efficiency of at least 5%, namely colon and ovary cancer cells, were
used for further studies. The luciferase activity was compared in
cell lines synthesising low vs high levels of the erbB-2 transcript
(HCT 116 vs COLO 320; OVCAR-3 vs SK-OV-3). In both colorectal
cell lines (HCT116 and COLO 320), the 6 kb promoter fragment
induced a 2.5-fold increase of the LUC activity compared to the
vector containing 200 bp of the promoter (Figure 3B, lane 4 and
3C, lane 4). The low-ERBB2-expressing ovary cancer cells,
OVCAR-3, showed an increase of the LUC activity with the
promoter size (Figure 3D). This increase was similar to that
observed in the colorectal cells (compare Figure 3B –D). Only
the p756-LUC construct increased the LUC activity in ERBB2-
overexpressing SK-OV-3 cells (Figure 3E, lane 2). The longer
promoter fragments downregulated the transcriptional activity to
the basal value (Figure 3E, lanes 3 and 4). It is interesting to note
that in this cell line the ERBB2 gene is amplified four-fold and
overexpressed more than 60 times (King et al, 1992 and personal
results, Table 1).
DISCUSSION
Around 30% of breast cancers overexpress the ERBB2 gene
and this is correlated with a poor prognosis. Besides gene
amplification, several investigators have described the involve-
ment of ETS family (Scott et al, 2000) and AP-2 family (Bates
and Hurst, 1997) transcription factors in the gene overex-
pression. ERBB2 overexpression has also been reported in
cancers of colon (Nakae et al, 1993; Kapitanovic et al, 1994;
Maurer et al, 1998), prostate (Ross et al, 1993; Morote et al, 1999),
ovary (Fajac et al, 1995) and pancreatic (Yamanaka et al, 1993)
origin. However, the mechanisms leading to increased expression
of the gene have not been investigated in these tumours.
Gene amplification is rare in these tumours and cannot account
for the observed increase in the mRNA or protein levels. To
our knowledge, this is the first attempt to understand the
molecular mechanisms leading to ERBB2 overexpression in non-
breast cancers.
First, we assessed p185
c-erbB-2
levels by ICC and by Western
blotting. One of the main observations of this study is that breast
and ovary cancer cell lines were characterised by a membrane
homogeneous staining, whereas in the non-breast cancer cells, the
staining was cytoplasmic and heterogeneous (Figure 1, Table 1).
Several truncated intracellular p185
c-erbB-2
fragments have been
described (Scott et al, 1993; Esparis-Ongando et al, 1999;
Christianson et al, 1998; Molina et al, 2002). These fragments,
which signal actively, might be responsible for the cytoplasmic
staining observed in most non-breast cancer cells. However, only
the full-length protein was detected by Western blotting in these
cells, which does not support the hypothesis that ICC detects a
truncated cytoplasmic protein. The cytoplasmic staining of
p185
c-erbB-2
has already been reported in prostate cancers
(Rosset et al, 1993). De Potter et al (1989) have described
the presence of a protein on the mitochondrial membrane,
appearing as granular staining in the cytoplasm. The significance
of the cytoplasmic staining in breast cancer cells is controversial,
since some authors did not observe a correlation between the
cytoplasmic protein and the mRNA levels (DiGiovanna, 1999; Ross
and Fletcher, 1999). However, in the non-breast cancer cells we
BT-474
MDA-MB-231
ZR-75.1 HepG2
LNCaP DU 145 PC-3
HCT 116
WiDr
HTm 29
COLO 205
COLO 320
OVCAR-3
SK-OV-3
PANC-1
Miapaca-2
HS766T
CF-PAC-1
SU.86.86
BxPC-3
Capan-2
12345678910 11 12 13 14 15 16 17 18 19 20 21
BT-474
MDA-MB-231
ZR-75.1
HepG2
LNCaP
DU 145
PC-3
HCT 116
WiDr
HTm 29
COLO 205
COLO 320
OVCAR-3
SK-OV-3
PANC-1
Miapaca-2
HS766T
CF-PAC-1
SU.86.86
BxPC-3
Capan-2
123456789
10 11 12 13 14 15 16 17 18 19 20 21
A
B
61
50
37
Figure 2 Distribution of AP-2 transcription factor in non-breast cancer
cell lines. (A) Western blot with10 mg (control, lanes 1 and 3) or 20 mg
(lanes 2 and 4 – 21) of crude nuclear extracts from breast and non-breast
cells. The arrowhead marks the 50 kDa molecular weight of AP-2
proteins. (B) EMSA assays with 2 mg (lanes 1 and 3) or 4 mg (lanes 2 and
4 – 21) of crude nuclear extracts. The arrowhead marks specific AP-2/DNA
complex.
ERBB2 gene expression in human cancer cells
D Vernimmen et al
902
British Journal of Cancer (2003) 89(5), 899 – 906 &2003 Cancer Research UK
Molecular and Cellular Pathology

have analysed, there was a good correlation between these
parameters. The mechanism by which p185
c-erbB-2
is mainly
cytoplasmic is unknown. The protein might not be properly
targeted to the membrane or, alternatively, might be internalised
(DiGiovanna, 1999).
We have characterised the ERBB2 gene copy number, mRNA
and protein levels in the tumour cell lines investigated in this
study. Gene amplification was detected only in BT-474, MDA-MB-
453 and SK-OV-3 cell lines, which is in good agreement with
already published data. LNCaP prostate carcinoma cells, three
pancreatic cells (Miapaca-2, Capan-2 and CF-PAC-1) and three
colon cancer cells (HCT116, COLO 205 and COLO 320) showed a
significant increase in erbB-2 mRNA levels without gene amplifi-
cation. Compared with breast cancer cells, the increase in the
transcript levels in these cells was low to moderate. HepG2
hepatocarcinoma cells expressed quite high levels of erbB-2 mRNA
and protein. Indeed, the mRNA level was about the same as in
COLO 320 cells but the protein level was much higher than in
colon cancer cells.
The increased levels of p185
c-erbB-2
have been shown to
affect the biology of the tumour. For instance, increased
p185
c-erbB-2
levels in prostate cancers were associated with
the passage from the androgen-dependent to the hormone-
independent status (Signoretti et al, 2000). ErbB2 might stimulate
the proliferation of colon cancer cells by upregulating COX2
(Mann et al, 2001).
In the ovary, prostate and pancreas cells, a good correlation
was observed between the relative protein and mRNA levels
(Figure 4). On the contrary, in colon cancers, we observed
an increase in mRNA levels while the protein levels were
unchanged. We suggest two explanations for this discrepancy.
First, the messenger RNA translation could be less efficient in
colon cancer cells. Indeed, Child et al (1999) have shown that
the erbB-2 transcript is translated with different efficiencies
in different cell lines. Second, the protein half-life might
be shorter in these cells. Future studies are needed to address
these questions.
As a first approach to the understanding of ERBB2 gene
expression regulation in non-breast cancer cell lines, we compared
ERBB2 expression levels with AP-2aprotein levels and with AP-2
DNA binding activity in these cells. As EMSA detects the binding
of AP-a,band gtranscription factors, this technique gives a more
0
0.5
1
1.5
2
2.5
3
123
4
12341234
0
0.5
1
1.5
2
2.5
3
3.5
134
0
0.5
1
1.5
2
2.5
3
3.5
4
LUC
LUC
LUC
LUC
p255
p756
p3838
p6047
1
2
3
4
Fold induction
Fold induction
0
0.5
1
1.5
2
2.5
3
3.5
Fold induction
Fold induction
2
A
BC
DE
Figure 3 Luc assays using different ERBB2 promoter constructs. (A)
Illustration of the different reporter vectors used. The promoter fragment
sizes are indicated in the hatched boxes. The luciferase activity was
measured in colon HCT 116 (B), COLO 320 (C) and ovary OVCAR-3
(D) and SK-OV-3 (E) cancer cells. The results are expressed as fold
induction compared to the level obtained with the p255-LUC vector. The
data are shown as the mean 7s.d. of triplicate experiments.
Ovary Prostate
OVCAR-3
SK-OV-3
DU145
PC-3
LNCaP
p185
 actin
Protein:
mRNA:
Gene copy:
p185
 actin
Protein:
mRNA:
Gene copy:
p185
 actin
Protein:
mRNA:
Gene copy:
17
60
1
14
1
1
111
1.5
0.5 5
12
Colon Liver
HTm 29
WiDr
HCT 116
COLO 205
COLO 320
HepG2
Pancreas
SU. 86.86
BxPC-3
HS 766T PANC-1
CF-PAC-1
Miapaca-2 Capan-2
2
244
3
111
13
1
1
11
1
113
1
9
1
1
111
11
1111
0.5
1.5
1.5 2.5 21 16 23
44
29
28
Figure 4 Expression of p185
c-erbB-2
and erbB-2 messenger RNA in
cancer cell lines. The first and the second lanes for each cell line correspond
to pre-confluent and confluent cultures respectively. In order to compare
the protein content in each cancer type, the value of one was given to the
cell line expressing the lowest level of p185
c-erbB-2
protein. The indicated
values for protein and mRNA correspond to those measured for confluent
cells.
ERBB2 gene expression in human cancer cells
D Vernimmen et al
903
British Journal of Cancer (2003) 89(5), 899 – 906&2003 Cancer Research UK
Molecular and Cellular Pathology